VAERS Explorer
Back to explore

Report #2869148

Received Oct 28, 2025

ER / ED visit
A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
—
Recovered
Recovered
Vaccinated
Sep 17, 2025
Onset
Sep 19, 2025
Days to onset
2
Hospital days
—

Vaccines (2)

TypeNameManufacturerDoseLotRoute / Site
RSVRSV (ABRYSVO)PFIZER\WYETHUNKUNKLA
TDAPTDAP (NO BRAND NAME)UNKNOWN MANUFACTURERUNKUNKRA

Symptoms (1)

Injection site pruritus

Symptom narrative

Itchy at injection site to the point of going to the ER; possible infection at injection site; This non-serious case was reported by a nurse via other manufacturer and described the occurrence of injection site itching in a 20-year-old patient who received DTPa (Reduced antigen) (Tdap Vaccine) for prophylaxis. Co-suspect products included RSV vaccine prot. subunit PreF 2v (Abrysvo) for prophylaxis. Concurrent medical conditions included anxiety (has anxiety), attention deficit hyperactivity disorder, depression and drug allergy (allergic to sulfa antibiotics). Concomitant products included Prenatal. On 17-SEP-2025, the patient received Tdap Vaccine (right arm). On 17-SEP-2025 09:45, the patient received Abrysvo (left arm). On 19-SEP-2025, 2 days after receiving Tdap Vaccine and Abrysvo, the patient experienced injection site itching (Verbatim: Itchy at injection site to the point of going to the ER) and injection site infection (Verbatim: possible infection at injection site). The patient was treated with cefalexin monohydrate (Keflex). On 22-SEP-2025, the outcome of the injection site itching and injection site infection were resolved (duration 3 days). It was unknown if the reporter considered the injection site itching and injection site infection to be related to Tdap Vaccine, Dtpa Vaccine Pre-Filled Syringe Device and Abrysvo. It was unknown if the company considered the injection site itching and injection site infection to be related to Tdap Vaccine, Dtpa Vaccine Pre-Filled Syringe Device and Abrysvo. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 07-OCT-2025 The patient received the Tdap Vaccine and Abrysvo and experienced itchy at the injection site to the point of going to the emergency room. The doctor gave antibiotic due to possible infection at injection site ad was treated with Keflex The patient did not receive any other vaccine within 4 weeks prior to the vaccinations. The batch number was not provided, and we are unable to contact the reporter.

Current illness

Anxiety (has anxiety); Attention deficit hyperactivity disorder; Depression; Drug allergy (allergic to sulfa antibiotics)

Other medications

Prenatal